191 related articles for article (PubMed ID: 34953080)
1. Therapeutic drug monitoring of posaconazole delayed release tablet while managing COVID-19-associated mucormycosis in a real-life setting.
Patel A; Patel K; Patel K; Shah K; Chakrabarti A
Mycoses; 2022 Mar; 65(3):312-316. PubMed ID: 34953080
[TBL] [Abstract][Full Text] [Related]
2. Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series.
Soman R; Chakraborty S; Joe G
Int J Infect Dis; 2022 Jul; 120():177-178. PubMed ID: 35405351
[TBL] [Abstract][Full Text] [Related]
3. Enteral feeding tube administration with therapeutic drug monitoring of crushed posaconazole tablets and opened isavuconazonium sulfate capsules.
Dieringer TD; Schaenman JM; Davis MR
J Antimicrob Chemother; 2022 Apr; 77(5):1417-1423. PubMed ID: 35174391
[TBL] [Abstract][Full Text] [Related]
4. Multicenter Epidemiologic Study of Coronavirus Disease-Associated Mucormycosis, India.
Patel A; Agarwal R; Rudramurthy SM; Shevkani M; Xess I; Sharma R; Savio J; Sethuraman N; Madan S; Shastri P; Thangaraju D; Marak R; Tadepalli K; Savaj P; Sunavala A; Gupta N; Singhal T; Muthu V; Chakrabarti A;
Emerg Infect Dis; 2021 Sep; 27(9):2349-2359. PubMed ID: 34087089
[TBL] [Abstract][Full Text] [Related]
5. Serum posaconazole levels among haematological cancer patients taking extended release tablets is affected by body weight and diarrhoea: single centre retrospective analysis.
Miceli MH; Perissinotti AJ; Kauffman CA; Couriel DR
Mycoses; 2015 Jul; 58(7):432-6. PubMed ID: 26102575
[TBL] [Abstract][Full Text] [Related]
6. Factors associated with subtherapeutic levels of oral posaconazole tablet: a detailed analysis from a tertiary care center in India.
Prayag PS; Panchakshari SP; Mahalle NP; Dhupad S; Patwardhan SA; Naik SS; Narawade S; Melinkeri S; Prayag AP
Int J Infect Dis; 2022 Nov; 124():76-80. PubMed ID: 36089153
[TBL] [Abstract][Full Text] [Related]
7. Utilization of posaconazole oral suspension or delayed-released tablet salvage treatment for invasive fungal infection.
Kim JH; Benefield RJ; Ditolla K
Mycoses; 2016 Nov; 59(11):726-733. PubMed ID: 27392814
[TBL] [Abstract][Full Text] [Related]
8. Drug repurposing of triazoles against mucormycosis using molecular docking: A short communication.
Mhatre S; Patravale V
Comput Biol Med; 2021 Sep; 136():104722. PubMed ID: 34358995
[TBL] [Abstract][Full Text] [Related]
9. Antifungal prophylaxis with posaconazole tablet and oral suspension in patients with haematologic malignancy: Therapeutic drug monitoring, efficacy and risk factors for the suboptimal level.
Oh J; Kang CI; Kim SH; Huh K; Cho SY; Chung DR; Lee SY; Jung CW; Peck KR
Mycoses; 2020 Jan; 63(1):89-94. PubMed ID: 31610064
[TBL] [Abstract][Full Text] [Related]
10. Retrospective Comparison of Posaconazole Levels in Patients Taking the Delayed-Release Tablet versus the Oral Suspension.
Durani U; Tosh PK; Barreto JN; Estes LL; Jannetto PJ; Tande AJ
Antimicrob Agents Chemother; 2015 Aug; 59(8):4914-8. PubMed ID: 26055378
[TBL] [Abstract][Full Text] [Related]
11. Posaconazole delayed-release tablets in paediatric haematology-oncology patients.
Mauro M; Colombini A; Perruccio K; Zama D; D'Amico MR; Calore E; Carraro F; Muggeo P; Tridello G; Baretta V; Cesaro S
Mycoses; 2020 Jun; 63(6):604-609. PubMed ID: 32246512
[TBL] [Abstract][Full Text] [Related]
12. Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study.
Yi WM; Schoeppler KE; Jaeger J; Mueller SW; MacLaren R; Fish DN; Kiser TH
Ann Clin Microbiol Antimicrob; 2017 Sep; 16(1):60. PubMed ID: 28893246
[TBL] [Abstract][Full Text] [Related]
13. Treatment by Posaconazole Tablets, Compared to Posaconazole Suspension, Does Not Reduce Variability of Posaconazole Trough Concentrations.
Gautier-Veyret E; Bolcato L; Roustit M; Weiss S; Tonini J; Brenier-Pinchart MP; Cornet M; Thiebaut-Bertrand A; Stanke-Labesque F
Antimicrob Agents Chemother; 2019 Oct; 63(10):. PubMed ID: 31358587
[TBL] [Abstract][Full Text] [Related]
14. Real-Life Assessment of the Safety and Effectiveness of the New Tablet and Intravenous Formulations of Posaconazole in the Prophylaxis of Invasive Fungal Infections via Analysis of 343 Courses.
Tverdek FP; Heo ST; Aitken SL; Granwehr B; Kontoyiannis DP
Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28507111
[TBL] [Abstract][Full Text] [Related]
15. Risk factors for subtherapeutic levels of posaconazole tablet.
Tang LA; Marini BL; Benitez L; Nagel JL; Miceli M; Berglund C; Perissinotti AJ
J Antimicrob Chemother; 2017 Oct; 72(10):2902-2905. PubMed ID: 29091205
[TBL] [Abstract][Full Text] [Related]
16. Retrospective analysis of goal drug level attainment of posaconazole for invasive fungal infection prophylaxis in patients with acute myeloid leukemia pre- and post-switch to tablet formulation.
Liebenstein TK; Widmer KM; Fallon MJ
J Oncol Pharm Pract; 2018 Dec; 24(8):599-603. PubMed ID: 28768441
[TBL] [Abstract][Full Text] [Related]
17. Single-centre study of therapeutic drug monitoring of posaconazole in lung transplant recipients: factors affecting trough plasma concentrations.
Jeong W; Snell GI; Levvey BJ; Westall GP; Morrissey CO; Wolfe R; Ivulich S; Neoh CF; Slavin MA; Kong DCM
J Antimicrob Chemother; 2018 Mar; 73(3):748-756. PubMed ID: 29211913
[TBL] [Abstract][Full Text] [Related]
18. Re: 'Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis' by Manesh et al.
Muthu V; Agarwal R; Chakrabarti A
Clin Microbiol Infect; 2023 Nov; 29(11):1461-1462. PubMed ID: 37473841
[No Abstract] [Full Text] [Related]
19. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Lewis RE; Albert ND; Kontoyiannis DP
Antimicrob Agents Chemother; 2014 Nov; 58(11):6767-72. PubMed ID: 25182639
[TBL] [Abstract][Full Text] [Related]
20. Short intravenous amphotericin B followed by oral posaconazole using a simple, stratified treatment approach for diabetes or COVID-19-associated rhino-orbito-cerebral mucormycosis: author's response.
Mukaka M; Manesh A; Varghese GM
Clin Microbiol Infect; 2023 Nov; 29(11):1463-1464. PubMed ID: 37516382
[No Abstract] [Full Text] [Related]
[Next] [New Search]
